Technical Analysis for MRUS - Merus N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.02% | |
| MACD Bearish Signal Line Cross | Bearish | 0.02% | |
| Wide Range Bar | Range Expansion | 0.02% | |
| Gapped Down | Weakness | 0.02% | |
| Lower Bollinger Band Touch | Weakness | 0.02% | |
| Stochastic Reached Overbought | Strength | -7.96% | |
| Upper Bollinger Band Walk | Strength | -7.96% | |
| Multiple of Ten Bearish | Other | -7.96% | |
| Overbought Stochastic | Strength | -7.96% | |
| Upper Bollinger Band Touch | Strength | -7.96% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 9 hours ago |
| 20 DMA Resistance | about 9 hours ago |
| 10 DMA Resistance | about 10 hours ago |
| 10 DMA Support | about 10 hours ago |
| 20 DMA Support | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/05/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 61.61 |
| 52 Week Low | 19.805 |
| Average Volume | 1,168,038 |
| 200-Day Moving Average | 36.70 |
| 50-Day Moving Average | 50.09 |
| 20-Day Moving Average | 55.35 |
| 10-Day Moving Average | 56.33 |
| Average True Range | 3.25 |
| RSI (14) | 50.74 |
| ADX | 32.16 |
| +DI | 27.14 |
| -DI | 26.93 |
| Chandelier Exit (Long, 3 ATRs) | 51.53 |
| Chandelier Exit (Short, 3 ATRs) | 58.68 |
| Upper Bollinger Bands | 60.11 |
| Lower Bollinger Band | 50.58 |
| Percent B (%b) | 0.41 |
| BandWidth | 17.22 |
| MACD Line | 2.01 |
| MACD Signal Line | 2.20 |
| MACD Histogram | -0.1909 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 64.85 | ||||
| Resistance 3 (R3) | 64.69 | 61.06 | 63.11 | ||
| Resistance 2 (R2) | 61.06 | 58.42 | 61.14 | 62.53 | |
| Resistance 1 (R1) | 57.76 | 56.78 | 59.41 | 57.92 | 61.96 |
| Pivot Point | 54.13 | 54.13 | 54.96 | 54.21 | 54.13 |
| Support 1 (S1) | 50.83 | 51.49 | 52.48 | 50.99 | 46.94 |
| Support 2 (S2) | 47.20 | 49.85 | 47.28 | 46.37 | |
| Support 3 (S3) | 43.90 | 47.20 | 45.79 | ||
| Support 4 (S4) | 44.06 |
